These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21174506)

  • 1. After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
    Rosenson RS
    Future Cardiol; 2011 Jan; 7(1):11-8. PubMed ID: 21174506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
    Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
    J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
    Rosenson RS; Elliott M; Stasiv Y; Hislop C;
    Eur Heart J; 2011 Apr; 32(8):999-1005. PubMed ID: 21081550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
    Nicholls SJ; Cavender MA; Kastelein JJ; Schwartz G; Waters DD; Rosenson RS; Bash D; Hislop C
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):71-5. PubMed ID: 22109255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
    Džavík V; Lavi S; Thorpe K; Yip PM; Plante S; Ing D; Overgaard CB; Osten MD; Lan J; Robbins K; Miner SE; Horlick EM; Cantor WJ
    Circulation; 2010 Dec; 122(23):2411-8. PubMed ID: 21098449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
    Rosenson RS; Fraser H; Goulder MA; Hislop C
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):539-44. PubMed ID: 21989792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
    Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid levels after acute coronary syndromes.
    Pitt B; Loscalzo J; Ycas J; Raichlen JS
    J Am Coll Cardiol; 2008 Apr; 51(15):1440-5. PubMed ID: 18402897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
    Karakas M; Koenig W
    IDrugs; 2009 Sep; 12(9):585-92. PubMed ID: 19697278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.
    Tekin A; Tekin G; Güzelsoy D; Kaya A; Gürel CV; Yiğit Z; Ulutin T
    Am J Cardiol; 2004 Jul; 94(2):206-9. PubMed ID: 15246903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.